ProMIS Neurosciences Inc. (PMN) Form 10-Q — Nov 12, 2026
ProMIS Neurosciences filed its Q3 2026 10-Q reporting a net loss of $8.2 million for the quarter and $28.1 million for the nine months ended September 30, 2026, with an accumulated deficit of $158.5 million and negative operating cash flow of $32.1 million for the nine months. The company said its January 2026 PIPE, which raised $70.1 million net, plus existing cash and short-term investments should fund operations through 2027, though it continues to warn it will need substantial additional funding and that financial statements were prepared on a going concern basis.
Key figures
- Cash Position
- existing cash and short-term investments expected to fund operations through 2027
- Q3 net loss
- 8161868
- Working capital
- 41800000
- Precise ad sites
- 21
- Q3 2025 net loss
- 11580126
- Pmn310 q3 expense
- 5171867
- Interim ariae rate
- 0% (no ARIA-E reported)
- Interim ariah rate
- 4.4% (all mild and asymptomatic)
- Shares outstanding
- 8996862
- Accumulated deficit
- 158500000
- Fully diluted shares
- 19334896
- Plasma ptau217 decline
- 68.5% of patients showed declines from baseline; pooled ~15% decline
- Csf mtbr tau243 decline
- 62.5% of patients showed declines; pooled ~13.3% decline
- Nine month financing cash
- 70102381
- Pmn310 nine month expense
- 19221406
- Jan 2026 pipe net proceeds
- 70100000
- Jan 2026 pipe gross proceeds
- 75500000
- Precise ad enrolled subjects
- 144
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.